Human immunodeficiency virus protease peptidomimetic

Application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease, J. Med. Chem 39 705 (1996). 

W. Potts, R. van Horn, K. Anderson, T. Blake, E. Garver, G. Joseph, G. Dreyer, A. Shu, R. Heys, K. L. Fong, Characterization of the Metabolites of the Peptidomimetic Human Immunodeficiency Virus Type 1 Protease Inhibitor SK F 107461 in Rats Using Liquid Chromatography/Mass Spectrometry , Drug Metab. Dispos. 1995, 23, 799 - 805. 

Chem., 39, 705 (1996). An Approach to Rapid Estimation of Relative Binding Affinities of Enzyme Inhibitors Application to Peptidomimetic Inhibitors of the Human Immunodeficiency Virus Type 1 Protease. 

Ritonavir is an inhibitor of the human immunodeficiency virus (HIV) protease which, in combination with nucleoside analogs (600 mg/b.i.d. p.o.), is indicated in the treatment of HIV infection. Ritonavir is a peptidomimetic inhibitor of both the HIV-1 and HIV-2 proteases. Inhibition of HIV protease renders the enzyme incapable of processing the gag-pol polyprotein precursor, which leads to production of noninfectious immature HIV particles. 

Y. S. Tsantrizos, Peptidomimetic Therapeutic Agents Targeting the Protease Enzyme of the Human Immunodeficiency Virus and Hepatitis C Virus , Acc. Chem. Res., 2008, 41, 1252. 

---